Products
Services
Applications
Resources Get started
Resource Centre
Back

Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia

Publication

Date: 7th August 2018 | Source: Nature Scientific Reports

Authors: Paola Orsini, Crescenzio F. Minervini, Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Angela Minervini, Nicoletta Coccaro, Giuseppina Tota, Paola Casieri, Luciana Impera, Elisa Parciante, Claudia Brunetti, Annamaria Giordano, Giorgina Specchia, Francesco Albano.

We report a customized gene panel assay based on multiplex long-PCR followed by third generation sequencing on nanopore technology (MinION), designed to analyze five frequently mutated genes in chronic lymphocytic leukemia (CLL): TP53, NOTCH1, BIRC3, SF3B1 and MYD88. For this purpose, 12 patients were selected according to specific cytogenetic and molecular features significantly associated with their mutational status. In addition, simultaneous analysis of the targets genes was performed by molecular assays or Sanger Sequencing. Data analysis included mapping to the GRCh37 human reference genome, variant calling and annotation, and average sequencing depth/error rate analysis. The sequencing depth resulted on average higher for smaller amplicons, and the final breadth of coverage of the panel was 94.1%. The error rate was about 6% and 2% for insertions/deletions and single nucleotide variants, respectively. Our gene panel allows analysis of the prognostically relevant genes in CLL, with two PCRs per patient. This strategy offers an easy and affordable workflow, although further advances are required to improve the accuracy of the technology and its use in the clinical field. Nevertheless, the rapid and constant development of nanopore technology, in terms of chemistry advances, more accurate basecallers and analysis software, offers promise for a wide use of MinION in the future.

Read the full text

Recommended for you

Open a chat to talk to our sales team
FAQs

FAQs

Search